Article
Novartis Gene Therapies president talks Zolgensma competition, path forward for new formulation
Rating:
0.0
Views:
57
Likes:
1
Library:
1
Novartis' Zolgensma is at a critical juncture. A new oral rival has just arrived, and its bid to expand into older spinal muscular atrophy patients just hit an FDA roadblock. But to hear Novartis Gene Therapies President David Lennon tell it, the company has both situations under control.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value